Table 1.
Patient characteristics based on LOXL2 expression
| LOXL2-positive (n = 50) | LOXL2-negative (n = 259) | p-value | |
|---|---|---|---|
| Age | 46.4 ± 10 | 46.2 ± 11 | 0.884 |
| Tumor size | 0.356 | ||
| >2 cm | 38 (76) | 180 (69) | |
| ≤2 cm | 12 (24) | 79 (31) | |
| Lymph node status | 0.760 | ||
| Metastasis | 25 (50) | 136 (53) | |
| No metastasis | 25 (50) | 123 (47) | |
| Stage | 0.448 | ||
| I | 8 (16) | 60 (23) | |
| II | 31 (62) | 138 (53) | |
| III | 11 (22) | 61 (24) | |
| Histologic gradea | 0.735 | ||
| I, II | 31 (61) | 165 (69) | |
| III | 17 (33) | 76 (31) | |
| ER | |||
| Positive | 23 (46) | 162 (63) | 0.029 |
| Negative | 27 (54) | 97 (37) | |
| PR | |||
| Positive | 26 (52) | 169 (63) | 0.075 |
| Negative | 24 (48) | 90 (37) | |
| HER2a,b | 0.625 | ||
| Positive | 9 (18) | 37 (14) | |
| Negative | 39 (78) | 196 (76) | |
| CDH1a | 0.385 | ||
| Positive | 34 (71) | 191 (77) | |
| Negative | 14 (29) | 58 (23) | |
| Subtypea,c | 0.022 | ||
| TN | 17 (34) | 47 (18) | |
| Non-TN | 31 (62) | 186 (72) |
ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor-2, TN Triple-negative
a
Data with missing values
b
HER2 positive was defined by three positive on IHC exam or amplification on FISH
c
Triple-negative was defined as a tumor with estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor-2-negative